Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

idelalisib

- PMLiVE

Gilead and Arcus drop A2R inhibitor in prostate cancer following early data analysis

The candidate is also being evaluated in second- and third-line metastatic colorectal cancer

- PMLiVE

BioNTech and Duality Biologics add third ADC candidate to oncology partnership

The companies announced the original agreement covering two antibody-drug conjugates in April

- PMLiVE

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

The company will gain the first refusal to one of Poseida’s clinical stage programmes

- PMLiVE

New study shows AI model can identify where patients’ cancers originated

The predictions from OncoNPC could enable doctors to choose targeted cancer treatments

- PMLiVE

MSD and Astex announce expansion to oncology drug discovery collaboration

Astex will receive $35m upfront plus milestone payments totalling $500m per programme

- PMLiVE

Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases in the US

- PMLiVE

AI-supported mammography screening shows promise in breast cancer detection

The AI-supported screening tool detected cancer in 244 people in the study

- PMLiVE

Merck’s Keytruda combination shows promise in late-stage breast cancer study

More than 290,000 people are expected to be diagnosed with breast cancer in the US this year

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

- PMLiVE

Pfizer and Flagship Pioneering sign drug discovery partnership worth up to $7bn

The partners will each invest $50m upfront to develop up to ten new drug candidates

- PMLiVE

US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

- PMLiVE

Gilead’s COVID-19 treatment approved by FDA for patients with severe renal impairment

Use of Veklury among this patient population has previously been limited

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links